Follow
Annexin Pharmaceuticals AB
Nasdaq First North GM (Sweden)
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived
Type
Ticker
ISIN
Market
SHARE
ANNX
SE0009664154
Nasdaq First North GM
Sweden (SE)
Details of share in Annexin Pharmaceuticals AB with ticker ANNX
Status
Active
Order book id
Amount of instruments
70 734 528
Par value
1.2000
Market cap
Currency
SEK
Segment
First North
First trading date
19 Apr 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
16.50 SEK
47.4M SEK
06 Mar - 23 Mar 2017
IPO in Annexin Pharmaceuticals AB
Type
Price
Pre-money valuation
Time
Files
Exercise
16.50-23.00 SEK
04 Dec - 15 Dec 2017
Option exercise terms for ANNX TO1
Type
Price
Pre-money valuation
Time
Files
Rights issue
4.40 SEK
26M SEK
02 May - 17 May 2018
Share issue in Annexin Pharmaceuticals AB
Type
Price
Pre-money valuation
Time
Files
Exercise
4.40 SEK
04 Mar - 15 Mar 2019
Option exercise terms for ANNX TO2
Type
Price
Pre-money valuation
Time
Files
Rights issue
1.15 SEK
20.3M SEK
07 Feb - 21 Feb 2020
Share issue in Annexin Pharmaceuticals AB
Type
Ticker
ISIN
Market
SHARE
ANNX
SE0009664154
Nasdaq First North GM
Sweden (SE)
Details of share in Annexin Pharmaceuticals AB with ticker ANNX
Status
Active
Order book id
Amount of instruments
70 734 528
Par value
1.2000
Market cap
Currency
SEK
Segment
First North
First trading date
19 Apr 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
16.50 SEK
47.4M SEK
06 Mar - 23 Mar 2017
IPO in Annexin Pharmaceuticals AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
4.40 SEK
26M SEK
02 May - 17 May 2018
Share issue in Annexin Pharmaceuticals AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
1.15 SEK
20.3M SEK
07 Feb - 21 Feb 2020
Share issue in Annexin Pharmaceuticals AB
Type
Ticker
ISIN
Market
OPTION
ANNX TO1
SE0009664196
Nasdaq First North GM
Sweden (SE)
Details of option in Annexin Pharmaceuticals AB with ticker ANNX TO1
Status
Archived
Order book id
136294
Amount of instruments
Market cap
Currency
SEK
Trading period
19 Apr 2017 - 26 Jan 2018
Terms
Holders of warrants have the right, for each warrant, to subscribe for a new share at a subscription price corresponding to 70% of a volume weighted average of the trading price of the Company's shares during the period 20 November - 1 December 2017. However, the subscription price cannot be less than SEK 16.50/share or exceed SEK 23/share.
Type
Price
Pre-money valuation
Time
Files
Exercise
16.50-23.00 SEK
04 Dec - 15 Dec 2017
Option exercise terms for ANNX TO1
Type
Ticker
ISIN
Market
OPTION
ANNX TO2
SE0011090232
Nasdaq First North GM
Sweden (SE)
Details of option in Annexin Pharmaceuticals AB with ticker ANNX TO2
Status
Archived
Order book id
157038
Amount of instruments
5 894 544
Market cap
Currency
SEK
Segment
First North
Trading period
27 Jun 2018 - 13 Mar 2019
Terms
One (1) warrant of series TO2 entitles the holder to subscribe for one (1) new share in the Company.
Type
Price
Pre-money valuation
Time
Files
Exercise
4.40 SEK
04 Mar - 15 Mar 2019
Option exercise terms for ANNX TO2
People
Number of Employees
4 people
Jamal El Mosleh
CEO
Carl-Fredrik Lindner
Chairman of the board
Johan Frostegård
Board member
Gisela Sitbon
Board member
Anders Haegerstrand
Board member
Lena Torlegård
Board member
Carl-Fredrik Lindner
Board member
Company Details
Sector
HEALTH CARE

Address
Norrtullsg 6
Zip code
113 29
City/district
Stockholm
Country
Sweden (SE)
Registration number
556960-9539
LEI code
5493000JP703HGPJEX27
First trade date
19 Apr 2017
Registration date
06 Feb 2014
Short name
Annexin Pharmaceuticals

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date